AMINO ACID DERIVED ENAMINONES: A STUDY IN RING FORMATION PROVIDING VALUABLE ASYMMETRIC SYNTHONS

Brandon J. Turunen and Gunda I. Georg*

Department of Medicinal Chemistry and Center for Methodology and Library Development, University of Kansas, 1251 Wescoe Hall, Drive Lawrence, Kansas 66045

1.	General experimental paragraph	S2
	Representative procedures and characterization data for 2 and 3	
	Characterization data for compounds 4-26 , 29 and 30	
	References	
5.	¹ H and ¹³ C spectra for compounds 2 , 4-19 , 21-26 , 29 , and 30	S18-S69

General experimental paragraph.

All commercially available reagents and solvents were used without further purification unless otherwise noted. Methylene chloride was dried by distillation from calcium hydride. Flash column chromatography was carried out on silica gel. TLC was conducted on silica gel 250 micron, F₂₅₄ plates. ¹H NMR spectra were recorded on 400 MHz or 500 MHz NMR instruments. Chemical shifts are reported in ppm with the solvent as internal standard (CDCl₃: 7.28 ppm). Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants (Hz) and assignment. ¹³C NMR spectra were recorded on 100 MHz or 125 MHz NMR spectrometers with complete proton decoupling. Chemical shifts are reported in ppm with the solvent as internal standard (CDCl₃: 77.0 ppm). High-resolution mass spectrometry was performed by the University of Kansas Mass Spectroscopy Service Laboratory. All new compounds were determined to be >95% as determined by ¹H NMR spectroscopy.

Representative procedure for N-Boc ynone preparation.

(S)-tert-Butyl 2-(2-(Methoxy(methyl)amino)-2-oxoethyl)piperidine-1-carboxylate (1a). (R)-2-(1-(tert-Butoxycarbonyl)piperidin-2-yl)acetic acid (1, 1.00 g, 4.0 mmol) was dissolved in anhydrous CH_2Cl_2 (100 mL) under argon atmosphere and cooled to -15 $\,$ C. To this solution was added N_iO -dimethylhydroxylamine HCl (0.42 g, 4.27 mmol) and N-

methylmorpholine (0.05 mL, 4.44 mmol) followed by EDCI (0.82 g, 4.27 mmol) in portions over 30 minutes then allowed to come to room temperature. After 2 hours the reaction was again cooled to 0 C and quenched by the addition of an ice cold 10% HCl solution (25 mL) and allowed to stir at this temperature for 5 minutes. The reaction was diluted with water (50 mL) and extracted with CH₂Cl₂ (x3). The combined organic layers were washed with saturated NaHCO₃ (x1), dried over Na₂SO₄, filtered and concentrated. This crude material was purified via flash chromatography (3 hexane/1 EtOAc) to provide 1.14 g of the amide as an oily solid (96%): ¹H NMR (400 MHz, CDCl₃, 50 C) δ 1.33-1.45 (bm, 1H) 1.43 (s, 9H), 1.44-1.52 (bm, 5H), 2.47-2.59 (m, 2H), 2.70 (bt, J = 13 Hz, 1H), 3.01 (s, 3H), 3.57 (s, 3H), 3.88 (bd, J = 13 Hz, 1H), 4.58 (bs, 1H); ¹³C NMR (100 MHz, CDCl₃, 50 C) δ 19.3, 25.7, 28.8, 32.4, 33.1, 39.7, 48.0, 61.6, 79.7, 155.1, 172.6; IR (neat) 3564, 2933, 1690, 1447, 1255 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ C₁₄H₂₇N₂O₄: 287.1971, found 287.1957; [α]²²_D -6.0 (c = 1.0, CHCl₃).

(*R*)-tert-Butyl 2-(2-Oxobut-3-ynyl)piperidine-1-carboxylate (2). The Weinreb amide (1a, 0.72 g, 2.52 mmol) was dissolved in anhydrous THF (40 mL) under argon atmosphere and cooled to 0 C. To this reaction vessel, was added dropwise, a 0.5 M solution of ethynyl magnesium bromide (12.6 mL, 6.3 mmol) in THF and allowed to come to room temperature. After 2 hours the reaction was judged complete by TLC (1 hexanes / 1 EtOAc) and again cooled to 0 C. The reaction was quenched by the addition of an ice cold 10% HCl solution (15 mL) and allowed to stir at this temperature for 5 minutes. The reaction was diluted with water and extracted with EtOAc (x3). The combined organic layers were washed with saturated NaHCO₃ (x1), dried over Na₂SO₄,

filtered and concentrated. This crude material was purified via flash chromatography (8 hexane/1 EtOAc) to provide 0.53 g of a colorless oil (84%): 1 H NMR (500 MHz, CDCl₃) δ 1.41-1.51 (m, 2H), 1.44 (s, 9H), 1.59-1.76 (m, 4H), 2.77-2.84 (m, 2H), 2.87-2.90 (m, 1H), 3.29 (s, 1H), 4.01 (bs, 1H), 4.85 (bs, 1H); 13 C NMR (125 MHz, CDCl₃) δ 18.8, 25.1, 28.3, 28.4, 39.1, 45.8, 47.4, 78.8, 79.8, 81.5, 154.5, 185.0; IR (neat) 3211, 2937, 2090, 1680, 1411, 1165 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+Na]⁺ $C_{14}H_{21}NO_{3}Na$: 274.1419, found 274.1419; $[\alpha]_{D}^{22}$ -38 (c = 0.65, CHCl₃).

Representative procedure for conversion of ynone to enaminone:

(*R*)-7,8,9,9a-Tetrahydro-1*H*-quinolizin-2(6*H*)-one (3). METHOD 1: Ynone (2, 72 mg, 0.48 mmol) was dissolved in a 4N HCl-dioxane solution (1.5 mL) and allowed to react for 15 minutes. After this time the dioxane and excess HCl were removed under reduced pressure and this residue placed under vacuum for 15 minutes. This material was then dissolved in MeOH (10 mL) and excess K_2CO_3 (a minimum of 4 equivalents) was added. The reaction was judged to be complete by TLC (10% MeOH/CH₂Cl₂) in 15 minutes. At this time CH_2Cl_2 was added, the reaction suction filtered, and the organic solvents concentrated. This residue was purified via flash chromatography (1-5% MeOH/CH₂Cl₂) to provide 37 mg (87%) of an off-white solid: Spectral data of the title compound was identical to that reported in the literature with the exception of optical rotation: $[\alpha]_{-D}^{22}$ -135 (c = 0.925, CHCl₃). Comparison to the reported value, $[\alpha]_{-D}^{22}$ -146 (c

= 0.885, CHCl₃), indicated an ee of 93%. This enantiomeric ratio was verified via chiral HPLC using a Baker Chiralcel OJ column. Conditions: isopropanol 2-15% in hexanes, 60 minutes, 0.5 mL/min, 30 °C. (-)-Enantiomer: $R_t = 40.1$ min; (+)-Enantiomer: $R_t = 41.6$ min. ee = 94%.

METHOD 2: The ynone 2 (28 mg, 0.11 mmol) was dissolved in anhydrous CH₂Cl₂ (10 mL) under an argon atmosphere and cooled to -78 C. A solution of TMS-I (0.03 mL, 0.11 mmol) in anhydrous CH₂Cl₂ (1 mL) was then added dropwise at this temperature. After 20 minutes at this temperature the reaction was allowed to warm to 0 C and additional TMS-I (0.03-0.11 mmol) was added until all starting material was consumed (TLC, 3 hexanes / 1 EtOAc). After 20 minutes the reaction was judged complete and this mixture was concentrated under reduced pressure and placed under vacuum for 15 minutes. This residue was then dissolved in MeOH (5 mL) and excess K₂CO₃ was added. The reaction was monitored via TLC (10% MeOH/CH₂Cl₂) and judged complete after 30 minutes. At this time CH₂Cl₂ was added and the resultant slurry suction filtered the organic layer concentrated. This residue was purified via flash chromatography (5% MeOH/CH₂Cl₂) to provide 16 mg (95%) enaminone 3. The enantiomeric excess using this method was not determined on this example.

Ynone characterization data (4-14):

tert-Butyl 2-(2-Oxopent-3-ynyl)piperidine-1-carboxylate (4). ¹H NMR (500 MHz, CDCl₃) δ 1.25-1.48 (m, 2H), 1.42 (s, 9H), 1.55-1.67 (m, 4H), 2.02 (s, 3H), 2.75-2.80 (m, 3H), 4.00 (bs, 1H), 4.81 (bs, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 4.1, 18.8, 25.2, 28.3, 39.2, 45.7, 47.6, 79.6, 80.3, 90.5, 154.6, 185.7; IR (neat) 2974, 2936, 2862, 2218, 1670, 1410, 1157 cm⁻¹; HRMS (ES+) *m/z* calc'd for [M+H]⁺ C₁₅H₂₄NO₃ : 266.1756, found 266.1750.

tert-Butyl 2-(2-Oxo-4-phenylbut-3-ynyl)piperidine-1-carboxylate (5). ¹H NMR (500 MHz, CDCl₃) δ 1.39-1.55 (m, 2H), 1.44 (s, 9H), 1.64-1.73 (m, 4H), 2.85 (dd, J = 14 Hz, 9 Hz, 2H), 2.97 (dd, J = 14 Hz, 7 Hz, 1H), 4.06 (bs, 1H), 4.89 (bs, 1H), 7.23-7.41 (m, 2H), 7.44-7.47 (m, 1H), 7.58 (d, J = 7 Hz, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 18.7, 25.2, 28.3, 39.1, 45.8, 47.8, 53.4, 79.6, 88.0, 91.0, 119.8, 128.5, 130.6, 133.0, 154.5, 185.6; IR (neat) 3410, 2359, 2202, 1654 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ $C_{20}H_{26}NO_3$: 328.1913, found 328.1907.

tert-Butyl **2-(2-Oxobut-3-ynyl)pyrrolidine-1-carboxylate (6).** ¹H NMR (500 MHz, CDCl₃, 50 C) δ 1.38 (s, 9H), 1.60-1.67 (bs, 1H), 1.72-1.80 (m, 2H), 2,00-2.09 (m, 1H),

2.52-2.59 (m, 1H), 3.19 (s, 1H), 3.22 (bm, 3H), 4.13-4.22 (bm, 1H); 13 C NMR (125 MHz, CDCl₃) δ 23.6, 28.4, 31.5, 46.8, 50.0, 53.4, 78.0, 79.5, 81.7, 154.5, 183.0; IR (neat) 3209, 2977, 2881, 2092, 1707, 1414, 1179 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ $C_{13}H_{20}NO_3$: 238.1443, found 238.1440.

tert-Butyl 2-(2-Oxopent-3-ynyl)pyrrolidine-1-carboxylate (7). ¹H NMR (500 MHz, CDCl₃, 50 C) δ 1.43 (s, 9H), 1.64 (bs, 1H), 1.78-1.99 (m, 2H), 1.99 (s, 3H), 2.00-2.08 (m, 1H), 2.45-2.53 (m, 1H) 2.82-3.10 (bs, 1H), 3.28-3.40 (m, 2H), 4.20 (bs, 1H); ¹³C NMR (125 MHz, CDCl₃) δ 3.8, 23.5, 28.4, 31.0, 46.6, 50.1, 53.6, 80.0, 80.5, 91.0, 154.5, 186.6; IR (neat) 2975, 2939, 2216, 1670, 1397, 1163 cm⁻¹; HRMS (ES+) *m/z* calc'd for [M+H]⁺ C₁₄H₂₂NO₃: 252.1600, found 252.1591.

tert-Butyl 2-(2-Oxo-4-phenylbut-3-ynyl)pyrrolidine-1-carboxylate (8). ¹H NMR (500 MHz, CDCl₃, 50 C) δ 1.40 (s, 9H), 1.60-1.66 (bs, 1H) 1.66-1.75 (m, 2H), 1.96-2.02 (m, 1H), 2.55-2.61 (m, 1H), 3.00-3.12 (bs, 1H), 3.19-3.29 (bs, 2H), 4.12-4.18 (m, 1H), 7.18-7.21 (m, 2H), 7.25-7.28 (m, 1H), 7.38-7.42 (m, 2H); ¹³C NMR (125 MHz, CDCl₃) δ 23.5, 28.6, 31.4, 36.7, 50.4, 54.0, 56.8, 80.0, 88.2, 91.3, 120.1, 128.5, 130.6, 133.0, 154.4,

186.2; IR (neat) 2974, 2878, 2203, 1695, 1395, 1168 cm⁻¹; HRMS (ES+) m/z calc'd for $[M+H]^+ C_{19}H_{24}NO_3$: 314.1756, found 314.1729.

(*S*)-tert-Butyl 4-Oxo-1-phenylhex-5-yn-2-ylcarbamate (9). ¹H NMR (400 MHz, CDCl₃) δ 1.41 (s, 9H), 2.76-2.97 (m, 3H), 2.77-2.84 (m, 1H), 3.30 (s, 1H), 4.23-4.31 (m, 1H), 4.89 (d, J = 8 Hz, 1H), 7.18-7.33 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 28.7, 40.6, 48.8, 49.0, 79.8, 79.9, 81.7, 127.1, 129.0, 129.8, 137.9, 155.5, 185.9; IR (neat) 3352, 3265, 2095, 1685 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ C₁₇H₂₂NO₃ : 288.1600, found 288.1596; $[\alpha]_{D}^{22}$ -7.0 (c = 0.55, CHCl₃)

(S)-tert-Butyl 4-Oxo-1-phenylhept-5-yn-2-ylcarbamate (10). ¹H NMR (400 MHz, CDCl₃) δ 1.38 (s, 9H), 2.00 (s, 3H), 2.67 (d, J = 6 Hz, 2H), 2.75-2.92 (m, 2H), 4.23 (bs, 1H), 4.97 (d, J = 8 Hz, 1H), 7.08-7.28 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 4.5, 28.7, 40.7, 48.7, 49.1, 79.6, 80.6, 91.5, 127.0, 128.9, 129.8, 138.2, 155.5, 186.6; IR (neat)

3350, 2975, 2929, 2219, 1699, 1164 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ $C_{18}H_{24}NO_3$: 302.1756, found 302.1761; $[\alpha]_D^{22}$ -2.0 (c = 0.65, CHCl₃).

tert-Butyl Methyl((trans)-2-propioloylcyclohexyl)carbamate (11).

1H NMR (400 MHz, CDCl₃, 50 C) δ 1.15-1.29 (m, 2H), 1.32-1.73 (m, 2H), 1.46 (s, 9H), 1.79-1.89 (m, 3H), 1.93-1.98 (m, 1H), 2.75 (bs, 3H), 2.77-2.88 (m, 1H), 3.25 (s, 1H), 4.00-4.23 (bm, 1H);

1SC NMR (125 MHz, CDCl₃, 50 C, rotomeric) δ 24.5, 25.1, 28.3, 28.8, 29.7, 55.3, 55.9, 56.8, 79.5, 80.2, 80.8, 155.1, 188.8; IR (neat) 3211, 2933, 2860, 2089, 1690, 1151 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ C₁₅H₂₄NO₃: 266.1756, found 266.1757.

tert-Butyl Methyl((cis)-2-propioloylcyclohexyl)carbamate (12). ¹H NMR (400 MHz, CDCl₃, 50 C) δ 1.15-1.8 (m, 5H), 1.46 (s, 9H), 1.87-1.90 (m, 1H), 2.04-2.09 (m, 1H), 2.14-2.18 (m, 1H), 2.79 (s, 3H), 3.18 (s, 1H), 3.44 (bs, 1H), 3.98 (bs, 1H); ¹³C NMR (125 MHz, CDCl₃, 50 C, rotomeric) δ 21.3, 25.7, 26.2, 27.7, 28.2, 29.5, 52.2, 56.1, 77.3, 79.5,

82.2, 155.6, 188.6; IR (neat) 3400, 2929, 2858, 2087, 1690, 1148 cm⁻¹; HRMS (ES+) *m/z* calc'd for [M+H]⁺ C₁₅H₂₄NO₃ : 266.1756, found 266.1749.

(2*S*,4*R*)-tert-Butyl 4-Hydroxy-2-(2-oxobut-3-ynyl)pyrrolidine-1-carboxylate (13). ¹H NMR (400 MHz, CDCl₃, 50 °C) δ 1.42 (s, 9H), 1.76-1.82 (bm, 1H), 2.12-2.17 (bm, 1H), 2.66 (dd, J = 16 Hz, 9 Hz, 1H), 2.90 (bs, 1H), 3.20 (bs, 1H), 3.31 (s, 1H), 3.33-3.42 (m, 2H), 4.27-4.34 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 28.8, 40.7, 50.5, 52.6, 55.0, 69.4, 79.6, 80.4, 82.0, 155.0, 185.4; IR (neat) 3400, 3250, 2990, 2900, 2100, 1700, 1400 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ C₁₃H₂₀NO₄ : 254.1392, found 254.1389; [α]²²_D -55 (c = 0.89, CHCl₃).

(2*S*,4*S*)-*tert*-Butyl 4-Hydroxy-2-(2-oxobut-3-ynyl)pyrrolidine-1-carboxylate (14). ¹H NMR (400 MHz, CDCl₃, 50 C) δ 1.47 (s, 9H), 1.85 (bd, J = 14 Hz, 1H), 2.03 (s, 1H), 2.26 (ddd, J = 14 Hz, 9 Hz, 5Hz, 1H), 3.08 (dd, J = 16 Hz, 9 Hz, 1H), 3.23 (s, 1H), 3.38 (bd, J = 12 Hz, 2H), 3.59 (dd, J = 12 Hz, 5 Hz, 1H), 4.27-4.34 (m, 1H), 4.43-4.47 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 28.9, 39.7, 51.1, 53.1, 55.4, 70.8, 78.8, 80.4, 82.2,

154.6, 186.0; IR (neat) 3400, 2975, 2090, 1680, 1400 cm⁻¹; HRMS (ES+) m/z calc'd for $[M+H]^+ C_{13} H_{20} NO_4$: 254.1392, found 254.1393; $[\alpha]_D^{22} -4$ (c = 0.6, CHCl₃).

Enaminone characterization data (15-25):

4-Methyl-7,8,9,9a-tetrahydro-1*H***-quinolizin-2**(6*H*)**-one** (**15**). ¹H NMR (400 MHz, CDCl₃) δ 1.37-1.86 (m, 6H), 1.95 (s, 3H), 2.25 (dd, J =10.6 Hz, 16.5 Hz, 1H), 2.48 (dd, J = 16.5 Hz, 5.7 Hz, 1H), 2.76-2.82 (m, 1H), 3.28-3.38 (m, 1H), 3.74-3.78 (m, 1H), 4.95 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.6, 24.1, 26.1, 31.8, 43.2, 48.5, 59.0, 102.1, 163.4, 191.8; IR (neat) 3444, 2934, 2855, 1626, 1557 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ C₁₀H₁₆NO: 166.1232, found 166.1234.

4-Phenyl-7,8,9,9a-tetrahydro-1*H***-quinolizin-2**(6*H*)**-one** (**16**). ¹H NMR (500 MHz, CDCl₃) δ 1.46-1.50 (m, 2H), 1.56-1.60 (m, 1H), 1.75-1.80 (m, 2H), 1.88-1.98 (m, 1H), 2.47 (dd, J = 16 Hz, 11 Hz, 1H), 2.60-2.66 (m, 2H), 3.50-3.58 (m, 2H), 5.09 (s, 1H), 7.28-7.46 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 23.8, 25.9, 31.3, 42.6, 50.3, 58.6,

103.3, 127.0, 128.5, 128.9, 136.7, 165.9, 191.5; IR (neat) 2932, 2853, 1640, 1541 cm⁻¹; HRMS (FAB+) *m/z* calc'd for [M+H]⁺ C₁₅H₁₈NO : 228.1388, found 228.1400.

2,3,8,8a-Tetrahydroindolizin-7(1*H***)-one (17).** ¹H NMR (400 MHz, CDCl₃) δ 1.61-1.70 (m, 1H), 1.86-1.95 (m, 1H), 2.05-2.10 (m, 1H), 2.21-2.44 (m, 3H), 3.42-3.54 (m, 2H), 3.66-3.76 (m, 1H), 4.91 (d, J = 7 Hz, 1H), 7.19 (d, J = 7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 24.8, 33.2, 41.9, 49.7, 58.5, 97.5, 150.4, 192.5; IR (neat) 3423, 297, 2879, 1617, 1559 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ $C_8H_{12}NO$: 138.1901, found 138.0911.

5-Methyl-2,3,8,8a-tetrahydroindolizin-7(1*H***)-one (18).** ¹H NMR (400 MHz, CDCl₃) δ 1.61-1.70 (m, 1H), 1.82-1.95 (m, 1H), 2.01 (s, 3H), 2.05-2.10 (m, 1H), 2.21-2.42 (m, 3H), 3.42-3.47 (m, 1H), 3.52-3.57 (m, 1H), 3.70-3.80 (m, 1H), 4.92 (s, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 20.9, 24.0, 33.1, 41.6, 47.3, 59.3, 98.4, 161.2, 191.7; IR (neat) 3397, 2918, 1597, 1531 cm⁻¹; HRMS (ES+) *m/z* calc'd for [M+H]⁺ C₉H₁₄NO : 152.1075, found 152.1093.

5-Phenyl-2,3,8,8a-tetrahydroindolizin-7(1*H***)-one (19).** ¹H NMR (400 MHz, CDCl₃) δ 1.75-1.85 (m, 1H), 1.85-2.00 (m, 1H), 2.01-2.09 (m, 1H), 2.30-2.40 (m, 1H), 2.41-2.54 (m, 2H), 3.27-3.31 (m, 1H), 3.48-3.52 (m, 1H), 4.04-4.07 (m, 1H), 5.10, (s, 1H), 7.38-7.45 (m, 5H); ¹³C NMR (100 MHz, CDCl₃) δ 24.9, 32.4, 41.9, 49.7, 59.3, 100.4, 128.0, 128.9, 130.2, 136.6, 163.3, 192.4; IR (neat) 3427, 2964, 2877, 1611, 1518, 1471 cm⁻¹; HRMS (ES+) *m/z* calc'd for [M+H]⁺ C₁₄H₁₆NO : 214.1232, found 214.1227.

(S)-2-Benzyl-2,3-dihydropyridin-4(1*H*)-one (20). Spectral data was identical to the reported values: $[\alpha]_D^{22}$ –150, (c = 0.65, CHCl₃); literature value = : $[\alpha]_D^{22}$ –151, (c = 0.225, CHCl₃).²

(*S*)-2-Benzyl-6-methyl-2,3-dihydropyridin-4(1*H*)-one (21). ¹H NMR (400 MHz, CDCl₃) δ 1.92 (s, 3H), 2.36 (dd, J = 16 Hz, 11.5 Hz, 1H), 2.48 (dd, J = 16 Hz, 5 Hz, 1H), 2.84-2.93 (m, 2H), 3.81-3.85 (m, 1H), 4.82 (s, 1H), 4.98 (s, 1H), 7.19-7.38 (m, 5H); ¹³C

NMR (100 MHz, CDCl₃) δ 21.6, 40.8, 41.7, 54.7, 100.1, 127.5, 129.4, 129.6, 137.3, 161.2, 191.6; IR (neat) 3244, 1608, 1597, 1531 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ C₁₃H₁₆NO: 202.1232, found 202.1234; $[\alpha]_{D}^{22}$ -190 (c = 1.6, CHCl₃).

(trans)-1-Methyl-4a,5,6,7,8,8a-hexahydroquinolin-4(1*H*)-one (22). ¹H NMR (500 MHz, CDCl₃) δ 0.95-1.04 (m, 1H), 1.10-1.28 (m, 2H), 1.30-1.39 (m, 1H), 1.70-1.85 (m, 2H), 2.00-2.08 (m, 1H), 2.13-2.15 (m, 1H), 2.32-2.35 (m, 1H), 2.89 (s, 3H), 2.92-3.06 (m, 1H) 4.96 (d, J = 7 Hz, 1H), 6.98 (d, J = 7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 23.5, 23.8, 24.0, 29.2, 38.5, 47.4, 61.1, 97.3, 154.2, 193.0; IR (neat) 3417, 2924, 2856, 1634, 1590, 1191 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ $C_{10}H_{16}NO$: 166.1232, found 166.1235.

(*cis*)-1-Methyl-4a,5,6,7,8,8a-hexahydroquinolin-4(1*H*)-one (23). ¹H NMR (500 MHz, CDCl₃) δ 1.23-1.32 (m, 2H), 1.37-1.42 (m, 2H), 1.50-1.57 (m, 1H), 1.57-1.66 (m, 1H), 1.77-1.87 (m, 1H), 2.10-2.18 (m, 1H), 2.56-2.64 (m, 1H), 2.99 (s, 3H), 3.30-3.38 (m, 1H), 4.87 (d, J = 7 Hz, 1H), 6.83 (d, J = 7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 22.8,

23.8, 24.3, 29.0, 30.6, 45.0, 60.1, 96.7, 153.6, 192.0; IR (neat) 2930, 2855, 1631, 1590, 1207 cm⁻¹; HRMS (ES+) *m/z* calc'd for [M+H]⁺ C₁₀H₁₆NO : 166.1232, found 166.1227.

(2*R*,8a*S*)-2-Hydroxy-2,3,8,8a-tetrahydroindolizin-7(1*H*)-one (24). ¹H NMR (400 MHz, CDCl₃) δ 1.84 (ddd, J = 15.5 Hz, 11.3 Hz, 4.2 Hz, 1H), 2.03 (dd, J = 12.9 Hz, 5.6 Hz, 1H), 2.36 (dd, J = 16.3 Hz, 16.3 Hz), 1H), 2.47 (dd, J = 16.1 Hz, 5.1 Hz, 1H), 3.00 (bs, 1H), 3.54 (d, J = 11.9 Hz, 1H), 3.75 (dd, J = 11.9 Hz, 4.4 Hz, 1H), 4.10-4.19 (m, 1H), 4.65 (t, J = 4.1 Hz, 1H), 5.00 (d, J = 7 Hz, 1H), 7.24 (d, J = 7 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 41.3, 42.1, 56.4, 58.6, 70.3, 97.8, 151.2, 192.7; IR (neat) 3400, 1580 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ C₈H₁₂NO₂: 154.0868, found 154.0853; [α]²²_D -490 (c = 0.45, CHCl₃).

(2R,8aR)-2-Hydroxy-2,3,8,8a-tetrahydroindolizin-7(1*H*)-one (*ent*-25). ¹H NMR (400 MHz, D₃CCOCD₃) δ 1.74 (ddd, J = 15.5 Hz, 9 Hz, 6.5 Hz, 1H), 2.05-2.08 (m, 1H), 2.22 (dd, J = 15.8 Hz, 5 Hz, 1H), 2.38 (dd, J = 15.8 Hz, 15.8 Hz, 1H), 2.51 (ddd, J = 6.4 Hz, 12.6 Hz, 6.4 Hz, 1H), 3.36 (dd, J = 10.7 Hz, 5.5 Hz, 1H), 3.69 (dd, J = 10.7 Hz, 6.5 Hz, 1H), 3.74-3.81 (m, 1H), 4.50-4.56 (m, 1H), 4.75 (d, J = 7.4 Hz, 1H), 7.30 (d J = 7.4 Hz; I NMR (100 MHz, D₃CCOCD₃) δ 41.4, 42.2, 57.0, 57.2, 70.0, 97.2, 150.1, 190.6; IR

(neat) 3320, 2871, 1614, 1560 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ $C_8H_{12}NO_2$: 154.0868, found 154.0862; $[\alpha]_D^{22}$ +780 (c = 0.90, CHCl₃).

Additional Compounds (26, 29, 30):


(*R*)-1-(Piperidin-2-yl)but-3-yn-2-one 2,2,2-Trifluoroacetic Acid (26). ¹H NMR (400 MHz, CHCl₃) δ 1.51-1.62 (m, 1H), 1.70 (dd, J = 24 Hz, 12 Hz, 1H), 1.77-1.99 (m, 4H), 3.00 (dd, J = 18 Hz, 6 Hz, 2H), 2.25 (bd, J = 18 Hz, 1H), 3.38 (s, 1H), 3.45-3.57 (bm, 2H), 9.22 (bd, J = 70 Hz, 2H-exchangable); ¹³C NMR (100 MHz, CDCl₃) δ 22.5, 22.6, 28.7, 45.5, 48.1, 52.8, 81.0, 81.3, 183.2; IR (neat) 2958, 2097, 1678, 1203, 1136 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ C₉H₁₄NO: 152.1075, found 152.1060.

(*R*,*E*)-4-Chloro-1-(piperidin-2-yl)but-3-en-2-one (29). ¹H NMR (400 MHz, CD₃OD) δ 1.55-1.80 (m, 3H), 1.81-1.99 (m, 3H), 2.96-3.17 (m, 3H), 3.30-3.41 (m, 2H), 3.50-3.64 (m, 1H), 6.66 (d, J = 13.7 Hz, 1H), 7.70 (d, J = 13.7 Hz, 1H); ¹³C NMR (100 MHz, CD₃OD) δ 22.0, 22.3, 42.9, 45.0, 52.9, 132.4, 139.2, 194.8; IR (neat) 3400, 2951, 1674, 1585 cm⁻¹; HRMS (FAB+) m/z calc'd for [M+H]⁺ C₉H₁₅NOC1 : 188.0842, found 188.0827; [α]²²_D +22 (c = 0.32, CHCl₃).


(*R*)-tert-Butyl 2-(4,4-Dimethoxy-2-oxobutyl)piperidine-1-carboxylate (30). ¹H NMR (400 MHz, CDCl₃) δ 1.38-1.68 (m, 6H), 1.46 (s, 9H), 2.63 (dd, J = 15 Hz, 6.3 Hz, 1H), 2.72-2.79 (m, 4H), 3.36 (s, 6H), 3.99 (bs, 1H), 4.73 (bs, 1H), 4.77 (t, J = 5.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 19.3, 25.7, 28.6, 28.8, 44.8, 47.0, 47.3, 54.2, 54.4, 80.0, 102.1, 155.2, 206.2; IR (neat) 3400, 2089, 1643 cm⁻¹; HRMS (ES+) m/z calc'd for [M+H]⁺ C₁₆H₃₀NO₅: 316.2124, found 316.2118; $[\alpha]_{D}^{22}$ +9.0 (c = 0.50, CHCl₃).


References:


- 1. Comins, D. L.; LaMunyon, D. H. J. Org. Chem. 1992, 57, 5807-5809.
- 2. Comins, D. L.; Zhang, Y.; Joseph, S. P. Org. Lett. 1999, 1, 657-659.



























































































10 NM p1(CX CX F1) F2	F1 - Proci S1 WC2 SF MDW SSB LB 68	F2 - Proc SI SF MDW SSB SSB LLB DCB	CPDPRG2 NUC2 PCPO2 PCPO2 PL2 PL13 PL13 SF02	NUC1 P1 PL1 SF01	Dete
20.00 20.00 0.00 242.517 30498.43 -7.539 -948.11 12.50282 1572.32703	953ing parametr 1024 OF 500.1300000 no 0 0.30	essing paramet 65536 125.7578008 0 1.00 1.00 1.40	CHANNEL f2 ***** waitzi6 195.00 -4.00 19.00 30.00 500.1325000	CHANNEL f1 13C 6.50 5.00 125.7719472	20031023 5 spect 15.39 5 spect 5 5 spect 5 5 spect 5 5 spect 6 5 5 spect 6 6 5 spect 6 6 5 spect 6 7 spect 6
CM CM OPM PPM H2 PPM H2 PPM H2 PPM H2/CM	ens ##12	ers Hz	08 08 08 08 08 08 08 08 08 08 08 08 08 0	MHZ	Sec C

4-50

